A hypertrophiás cardiomyopathia klinikai és molekuláris genetikája.

Translated title of the contribution: Clinical and molecular genetics of hypertrophic cardiomyopathy

R. Sepp, M. Csanády

Research output: Contribution to journalArticle

Abstract

Recent developments in molecular genetics have allowed to identify mutations in seven genes coding the beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains and troponin I causing hypertrophic cardiomyopathy. These mutations affect critical, evolutionary conserved nucleotides of these genes and influence vital functions of the encoded proteins. As all seven genes encodes sarcomeric proteins in the heart muscle, hypertrophic cardiomyopathy is regarded these days as a disease of the sarcomer. Recent data indicate that some mutations are associated with "malignant" clinical picture, with rapidly developing, severe symptoms of the disease and increased risk of sudden cardiac death while other mutations bear a more favourable prognosis. Apart of the disease causing mutation other factors, including disease modifier genes, are likely to make an impact on the clinical appearance of hypertrophic cardiomyopathy. The knowledge provided by molecular genetics influences the clinical management of the disease even today and based on the investigation of mutation carrying patients new diagnostic criteria was proposed for hypertrophic cardiomyopathy. The challenge for the future is the establishment of routine genetic diagnostics and the development of possible gene therapy.

Original languageHungarian
Pages (from-to)1965-1971
Number of pages7
JournalOrvosi Hetilap
Volume139
Issue number33
Publication statusPublished - Aug 16 1998

Fingerprint

Hypertrophic Cardiomyopathy
Molecular Biology
Mutation
Ventricular Myosins
Modifier Genes
Genes
Tropomyosin
Troponin T
Troponin I
Myosin Heavy Chains
Sudden Cardiac Death
Disease Management
Genetic Therapy
Myocardium
Proteins
Nucleotides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hypertrophiás cardiomyopathia klinikai és molekuláris genetikája. / Sepp, R.; Csanády, M.

In: Orvosi Hetilap, Vol. 139, No. 33, 16.08.1998, p. 1965-1971.

Research output: Contribution to journalArticle

@article{ac96a792ba83433d9bda95ed5412d2bf,
title = "A hypertrophi{\'a}s cardiomyopathia klinikai {\'e}s molekul{\'a}ris genetik{\'a}ja.",
abstract = "Recent developments in molecular genetics have allowed to identify mutations in seven genes coding the beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains and troponin I causing hypertrophic cardiomyopathy. These mutations affect critical, evolutionary conserved nucleotides of these genes and influence vital functions of the encoded proteins. As all seven genes encodes sarcomeric proteins in the heart muscle, hypertrophic cardiomyopathy is regarded these days as a disease of the sarcomer. Recent data indicate that some mutations are associated with {"}malignant{"} clinical picture, with rapidly developing, severe symptoms of the disease and increased risk of sudden cardiac death while other mutations bear a more favourable prognosis. Apart of the disease causing mutation other factors, including disease modifier genes, are likely to make an impact on the clinical appearance of hypertrophic cardiomyopathy. The knowledge provided by molecular genetics influences the clinical management of the disease even today and based on the investigation of mutation carrying patients new diagnostic criteria was proposed for hypertrophic cardiomyopathy. The challenge for the future is the establishment of routine genetic diagnostics and the development of possible gene therapy.",
author = "R. Sepp and M. Csan{\'a}dy",
year = "1998",
month = "8",
day = "16",
language = "Hungarian",
volume = "139",
pages = "1965--1971",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - A hypertrophiás cardiomyopathia klinikai és molekuláris genetikája.

AU - Sepp, R.

AU - Csanády, M.

PY - 1998/8/16

Y1 - 1998/8/16

N2 - Recent developments in molecular genetics have allowed to identify mutations in seven genes coding the beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains and troponin I causing hypertrophic cardiomyopathy. These mutations affect critical, evolutionary conserved nucleotides of these genes and influence vital functions of the encoded proteins. As all seven genes encodes sarcomeric proteins in the heart muscle, hypertrophic cardiomyopathy is regarded these days as a disease of the sarcomer. Recent data indicate that some mutations are associated with "malignant" clinical picture, with rapidly developing, severe symptoms of the disease and increased risk of sudden cardiac death while other mutations bear a more favourable prognosis. Apart of the disease causing mutation other factors, including disease modifier genes, are likely to make an impact on the clinical appearance of hypertrophic cardiomyopathy. The knowledge provided by molecular genetics influences the clinical management of the disease even today and based on the investigation of mutation carrying patients new diagnostic criteria was proposed for hypertrophic cardiomyopathy. The challenge for the future is the establishment of routine genetic diagnostics and the development of possible gene therapy.

AB - Recent developments in molecular genetics have allowed to identify mutations in seven genes coding the beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains and troponin I causing hypertrophic cardiomyopathy. These mutations affect critical, evolutionary conserved nucleotides of these genes and influence vital functions of the encoded proteins. As all seven genes encodes sarcomeric proteins in the heart muscle, hypertrophic cardiomyopathy is regarded these days as a disease of the sarcomer. Recent data indicate that some mutations are associated with "malignant" clinical picture, with rapidly developing, severe symptoms of the disease and increased risk of sudden cardiac death while other mutations bear a more favourable prognosis. Apart of the disease causing mutation other factors, including disease modifier genes, are likely to make an impact on the clinical appearance of hypertrophic cardiomyopathy. The knowledge provided by molecular genetics influences the clinical management of the disease even today and based on the investigation of mutation carrying patients new diagnostic criteria was proposed for hypertrophic cardiomyopathy. The challenge for the future is the establishment of routine genetic diagnostics and the development of possible gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032537858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032537858&partnerID=8YFLogxK

M3 - Article

C2 - 9734214

AN - SCOPUS:0032537858

VL - 139

SP - 1965

EP - 1971

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -